Logo

PharmaShots Weekly Snapshots (October 10 - 14, 2022)

Share this
PharmaShots Weekly Snapshots (October 10 - 14, 2022)

PharmaShots Weekly Snapshots (October 10 - 14, 2022)

Bio-Thera Reports First Patient Dosing in P-I Study of BAT2606, a Proposed Biosimilar of Nucala (mepolizumab) for Severe Asthma

Published: Oct 14, 2022| Tags: Bio-Thera Solutions, BAT2606, Nucala, mepolizumab, Severe Asthma, Clinical Trial, P-I Study

Enliven Therapeutics Entered into a Definitive Merger Agreement with Imara for ~$594.1M

Published: Oct 14, 2022| Tags: Enliven Therapeutics, Merger Agreement, Imara, ELVN-002, ELVN-001, lung cancer, ~$574M, M&A

BridgeBio Pharma Presents P-I/II (CANaspire) Trial Results of BBP-812 for the Treatment of Canavan Disease at CNS 2022

Published: Oct 14, 2022| Tags: BridgeBio Pharma, BBP-812, Canavan Disease, Clinical Trial, P-I/II CANaspire Trial

GSK Reports P-III (AReSVi-006) Study Results of RSVPreF3 OA for the Treatment of Respiratory Syncytial Virus

Published: Oct 14, 2022| Tags: GSK, RSVPreF3 OA, Respiratory Syncytial Virus, Clinical Trial, P-III AReSVi-006 Study

AdAlta Collaborated with GPCR Therapeutics for Novel Therapies to Treat Cancer

Published: Oct 14, 2022| Tags: AdAlta, GPCR Therapeutics, Novel Therapies, Cancer, CXCR4-B2AR, AD-214, Pharma

Edgewise Therapeutics Reports 6-Month Interim (ARCH) Study Results of EDG-5506 for Becker Muscular Dystrophy

Published: Oct 14, 2022| Tags: Edgewise Therapeutics, EDG-5506, Becker Muscular Dystrophy, Clinical Trial, ARCH Study

Regeneron Reports the US FDA’s Acceptance of sBLA for Priority Review of Eylea to Treat Retinopathy of Prematurity

Published: Oct 13, 2022| Tags: Regeneron, Eylea, aflibercept, Retinopathy, Prematurity, Regulatory, US, FDA, sBLA, Priority Review

NanoString Collaborated with Visiopharm to Co-develop Integrated Workflows for Spatial Biology Solutions

Published: Oct 13, 2022| Tags: NanoString, Visiopharm, Integrated Workflows, GeoMx, AtoMx, Spatial Biology Solutions, Pharma

Pasithea Therapeutics Acquires AlloMek Therapeutics and Expands CNS-Focused Drug Development Pipeline

Published: Oct 13, 2022| Tags: Pasithea Therapeutics, AlloMek Therapeutics, CIP-137401, neurofibromatosis type 1, Noonan syndrome, Acquires, M&A

Astellas to Present P-III (SKYLIGHT 4) Study of Fezolinetant for Vasomotor Symptoms Associated with Menopause at NAMS 2022

Published: Oct 13, 2022| Tags: Astellas, Fezolinetant, Vasomotor Symptoms, Menopause, P-III, SKYLIGHT 4 Study, NAMS, 2022

Tavros Therapeutics Entered into a Five-Year Collaboration Agreement with Vividion Therapeutics to Discover and Enhance Targeted Oncology Programs

Published: Oct 13, 2022| Tags: Tavros Therapeutics, Vividion Therapeutics, Oncology Programs, Pharma

Pfizer and BioNTech Receive the US FDA’s Emergency Use Authorization for 10-µg Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booste

Published: Oct 13, 2022| Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine, 10-µg, Booster, US, FDA, Emergency Use Authorization

BeiGene Reports P-III (ALPINE) Trial Results of Brukinsa (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia

Published: Oct 12, 2022| Tags: BeiGene, Brukinsa, zanubrutinib, Chronic Lymphocytic Leukemia, Clinical Trial, P-III ALPINE Trial

BridgeBio Pharma Reports First Patient Dosing in P-I/II Trial for BBP-398 + Lumakras (sotorasib) to Treat Non-Small Cell Lung Cancer

Published: Oct 12, 2022| Tags: BridgeBio Pharma, BBP-398, Lumakras, sotorasib, Non-Small Cell Lung Cancer, Clinical Trial, P-I/II Trial

Gilead Reports the US FDA's Acceptance of Trodelvy's sBLA for Priority Review to Treat Pre-Treated HR+/HER2- Metastatic Breast Cancer

Published: Oct 12, 2022| Tags: Gilead, Trodelvy, HR+/HER2- Metastatic Breast Cancer, regulatory, sBLA, Priority Review, US, FDA

Genentech Presents Two Year P-II (JEWELFISH) Study Results of Evrysdi (risdiplam) for the Treatment of Spinal Muscular Atrophy at WMS 2022

Published: Oct 12, 2022| Tags: Genentech, Evrysdi, risdiplam, Spinal Muscular Atrophy, WMS, 2022, Clinical Trial, JEWELFISH Study

AstraZeneca Entered into a Research Collaboration with Illumina to Accelerate AI-based Drug Target Discovery

Published: Oct 12, 2022| Tags: AstraZeneca, Illumina, AI-based Drug Target Discovery, PrimateAI, SpliceAI

Eli Lilly Entered into a Research Collaboration and License Agreement with Nimbus Therapeutics for Small Molecule Activators of AMPK

Published: Oct 12, 2022| Tags: Eli Lilly, Nimbus Therapeutics, Small Molecule Activators, AMPK, metabolic disorders

HanAll's Licensed Partner Entered into an Exclusive Sublicense Agreement with CSPC NBP Pharma for Batoclimab

Published: Oct 11, 2022| Tags: HanAll, CSPC, NBP Pharma, Batoclimab, HL161BKN, HL036, tanfanercept, dry eye disease

Regeneron Presents P-III Trial Results of Dupixent (dupilumab) for Eosinophilic Esophagitis in Children Aged 1 to 11 Years at UEG 2022

Published: Oct 11, 2022| Tags: Regeneron, Dupixent, dupilumab, Eosinophilic Esophagitis, P-III Trial, UEG, 2022

JW Therapeutics Receives the NMPA’s Approval for Carteyva (relmacabtagene autoleucel) sNDA to Treat Relapsed or Refractory Follicular Lymphoma

Published: Oct 11, 2022| Tags: JW Therapeutics, Carteyva, relmacabtagene autoleucel, sNDA, Follicular Lymphoma, NMPA Approval, Regulatory

Brainomix Collaborated with UK Government-Funded NCIMI for AI-Powered Technology in Lung Cancer

Published: Oct 11, 2022| Tags: Brainomix, NCIMI, AI-Powered Technology, e-ACT, Lung Cancer, MedTech

Merck Reports P-III (STELLAR) Trial Results of Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Published: Oct 11, 2022| Tags: Merck, Sotatercept, Pulmonary Arterial Hypertension, Clinical Trial, P-III STELLAR Trial

Janssen Presents P-III (UNIFI) Study Results of Stelara (ustekinumab) for Active Ulcerative Colitis at UEG 2022

Published: Oct 11, 2022| Tags: Janssen, Stelara, ustekinumab, Active Ulcerative Colitis, P-III UNIFI Study, UEG, 2022

Janssen Presents P-IIa (VEGA) PoC Study Results of Guselkumab + Golimumab for Active Ulcerative Colitis at UEG 2022

Published: Oct 10, 2022| Tags: Janssen, Guselkumab, Golimumab, Active Ulcerative Colitis, P-IIa (VEGA) PoC Study, Clinical Trials, UEG, 2022

BIOCORP Signs an Agreement with Merck KGaA to Co-develop New Bluetooth-Enabled Drug Delivery Device

Published: Oct 10, 2022| Tags: BIOCORP, Merck KGaA, New Bluetooth-Enabled Drug Delivery Device, Mallya devices, Sanofi, Novo Nordisk, DigiHealth

Ascletis Reports Patients Dosing in Multiple-Dose Escalation P-I Clinical Trial of ASC10 for COVID-19

Published: Oct 10, 2022| Tags: Ascletis, Multiple-Dose Escalation, P-I Clinical Trial, ASC10, COVID-19

Pfizer and BioNTech’s Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster Receives Health Canada Authorization in Individuals Aged ≥12 Years

Published: Oct 10, 2022| Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine, Health Canada, Authorization, Regulatory

Innovent’s Cyramza (ramucirumab) Receives NMPA’s Approval for the Treatment of Hepatocellular Carcinoma

Published: Oct 10, 2022| Tags: Innovent, Cyramza, ramucirumab, Hepatocellular Carcinoma, Regulatory, NMPA Approval

Sciwind Biosciences Initiates the First Patient Dosing of XW014 in P-I for the Treatment of Obesity and Type 2 Diabetes

Published: Oct 10, 2022| Tags: Sciwind Biosciences, XW014, Obesity, Type 2 Diabetes, Clinical Trial, US

Related Post: PharmaShots Weekly Snapshots (October 03 - 07, 2022)


Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions